[
  {
    "ts": null,
    "headline": "Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y",
    "summary": "EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.",
    "url": "https://finnhub.io/api/news?id=8859582fff9b1f18ba9740b9bbe9ab15187f60a1d10b4c39d44a68fb123dd874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762875420,
      "headline": "Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y",
      "id": 137448991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.",
      "url": "https://finnhub.io/api/news?id=8859582fff9b1f18ba9740b9bbe9ab15187f60a1d10b4c39d44a68fb123dd874"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance",
    "summary": "Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...",
    "url": "https://finnhub.io/api/news?id=8ceb092f6fa1a0898b24f10f957d8ad5d8aead448d607b2687abf8002ce2554f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762859560,
      "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance",
      "id": 137448992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...",
      "url": "https://finnhub.io/api/news?id=8ceb092f6fa1a0898b24f10f957d8ad5d8aead448d607b2687abf8002ce2554f"
    }
  },
  {
    "ts": null,
    "headline": "Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results",
    "summary": "With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]",
    "url": "https://finnhub.io/api/news?id=c8fd7804367b2efd83728f46f316d2ca2ed2117ef356a49f6129709fd82e57bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762823792,
      "headline": "Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results",
      "id": 137437904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]",
      "url": "https://finnhub.io/api/news?id=c8fd7804367b2efd83728f46f316d2ca2ed2117ef356a49f6129709fd82e57bf"
    }
  }
]